Results 191 to 200 of about 81,525 (242)
Barriers to Buprenorphine Initiation in Patients Using Fentanyl.
JAMA Netw OpenKawasaki SS +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Pharmacology and Therapeutics, 1980
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham +3 more
openaire +2 more sources
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham +3 more
openaire +2 more sources
Drugs, 2003
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Drug and Alcohol Dependence, 1985
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. Its pharmacological profile is determined primarily by partial agonism at mu-receptors and unusually slow kinetics at these receptors. Its intrinsic activity is such that in nearly all clinical situations it is as effective an analgesic as morphine ...
openaire +2 more sources
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. Its pharmacological profile is determined primarily by partial agonism at mu-receptors and unusually slow kinetics at these receptors. Its intrinsic activity is such that in nearly all clinical situations it is as effective an analgesic as morphine ...
openaire +2 more sources
Journal of the American Academy of Child & Adolescent Psychiatry, 2023
Paul E.A. Glaser +3 more
openaire +1 more source
Paul E.A. Glaser +3 more
openaire +1 more source